Indian stocks: Visit www.stage2stocks.com →

Imunon, Inc.

Stage 4 · Declining · week 61

As of Oct 22, 2026, Imunon is in Stage 4, the downtrend phase, now in week 61 (since Aug 12, 2025). It closed at $1.25, 74.5% below its 52-week high and below its 200-day average, which is falling.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. More about the company

$1.25
+2.65% today
$7.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is IMNN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 30w
S4 16w
S4 62w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 30w → S1 5w → S2 10w → S3 5w → S2 1w → S3 9w → S4 16w → S1 13w → S4 4w → S1 1w → S2 6w → S3 4w → S4 62w current
Total tracked: 166 weeks across 13 stage runs.

IMNN among Biotechnology445th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…445IMNNStage 4 · wk 6113−15.0%
vs 52W High
-74.5%
$0.99 lo$4.91 hi
74.5% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 61
1w13w26w
Week 61, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-46.1%
200 DMA: $2.32 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.32x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-15.0%
3M
-17.2%
6M
-56.3%
YTD
-68.4%
1Y
-75.3%
Scan Membership
Breakout Watch
Latest: 2025-05-30
6 appearances in last 60 days. First seen: 2020-06-05.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 61 · Vol 0.32x
2026-10-21S4
Wk 61 · Vol 2.51x
2026-10-20S4
Wk 60 · Vol 0.43x
2026-10-19S4
Wk 60 · Vol 0.91x
2026-10-16S4
Wk 60 · Vol 0.54x
2026-10-15S4
Wk 60 · Vol 0.38x
2026-10-14S4
Wk 60 · Vol 0.18x
2026-10-13S4
Wk 59 · Vol 0.38x
2026-10-12S4
Wk 59 · Vol 0.41x
2026-10-09S4
Wk 59 · Vol 2.11x
2026-10-08S4
Wk 59 · Vol 1.18x
2026-10-07S4
Wk 59 · Vol 0.98x
Moving averages & range
50 DMA
$1.39
200 DMA
$2.32
52W High
$4.91
52W Low
$0.99
5D Low
$0.99
Resistance levels (recent highs)
20d High
$1.41
60d High
$1.67
120d High
$2.80
250d High
$4.85
Next resistance
+12.8%
to 20d High
ROE
-429.7%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.0

Imunon: quick answers

What stage is Imunon in?

As of Oct 22, 2026, Imunon (IMNN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 12, 2025 and is in week 61. What the four stages mean

Is Imunon in an uptrend?

No. Imunon is in a Stage 4 downtrend. It trades 46.1% below its 200-day average, which is falling.

How far is Imunon from its 52-week high?

Imunon closed at $1.25 on Oct 22, 2026, 74.5% below its 52-week high of $4.91. Its 52-week low is $0.99.

How has Imunon performed over the past year?

As of Oct 22, 2026, Imunon is down 75.3% over the past year and down 68.4% so far in 2026.

Which sector and industry is Imunon in?

Imunon is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.